- Home
- SPFI vs IVA Comparison
SPFI vs IVA Comparison
Compare SPFI & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- IVA
- Stock Information
- Founded
- SPFI 1941
- IVA 2011
- Country
- SPFI United States
- IVA France
- Employees
- SPFI N/A
- IVA N/A
- Industry
- SPFI Major Banks
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- IVA Health Care
- Exchange
- SPFI Nasdaq
- IVA Nasdaq
- Market Cap
- SPFI 662.8M
- IVA 769.0M
- IPO Year
- SPFI 2019
- IVA 2020
- Fundamental
- Price
- SPFI $38.28
- IVA $5.54
- Analyst Decision
- SPFI Buy
- IVA Strong Buy
- Analyst Count
- SPFI 3
- IVA 7
- Target Price
- SPFI $41.67
- IVA $16.00
- AVG Volume (30 Days)
- SPFI 51.4K
- IVA 69.2K
- Earning Date
- SPFI 10-22-2025
- IVA 09-29-2025
- Dividend Yield
- SPFI 1.56%
- IVA N/A
- EPS Growth
- SPFI 19.09
- IVA N/A
- EPS
- SPFI 3.20
- IVA N/A
- Revenue
- SPFI $199,001,000.00
- IVA $19,929,536.00
- Revenue This Year
- SPFI $13.41
- IVA N/A
- Revenue Next Year
- SPFI $6.10
- IVA N/A
- P/E Ratio
- SPFI $12.03
- IVA N/A
- Revenue Growth
- SPFI 7.49
- IVA N/A
- 52 Week Low
- SPFI $30.01
- IVA $1.60
- 52 Week High
- SPFI $42.38
- IVA $6.55
- Technical
- Relative Strength Index (RSI)
- SPFI 42.61
- IVA 49.33
- Support Level
- SPFI $37.65
- IVA $5.59
- Resistance Level
- SPFI $39.59
- IVA $6.55
- Average True Range (ATR)
- SPFI 1.15
- IVA 0.36
- MACD
- SPFI -0.14
- IVA -0.04
- Stochastic Oscillator
- SPFI 18.83
- IVA 20.38
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.